A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the pharmacokinetics of Retrovir (AZT) administered orally as 1 of 3 doses in the
treatment of patients with severe clinical and laboratory manifestations of HIV infection. To
compare the safety and tolerance of AZT administered 2, 3, and 6 x daily to these patients.